-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $205

Benzinga·11/17/2025 17:37:01
Listen to the news
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $185 to $205.